55 research outputs found
Cytokine Signaling and Mitogenic Responsiveness of B Cell Precursor Acute Lymphoblastic Leukemia
CD20 and CD40 mediated mitogenic responses in B-lineage acute lymphoblastic leukaemia
Activation of CD20, a cross-membrane ion channel, induces cell cycle progression from G0 to G1 in B lymphocytes. Subsequent activation of CD40, a membrane receptor of the nerve growth factor receptor superfamily, transits the B cells to the S phase. CD40 may also act synergistically in combination with IL-4 (B lymphocytes) or IL-3/IL-7 (B-cell precursors). We investigated the proliferative responses of B-lineage acute lymphoblastic leukaemia (ALL) cells to CD20/CD40 activation. In 18/56 ALL cases, CD20 activation resulted in significant increases in DNA synthesis. Similar, although more moderate, effects were seen of activation of CD40 in 10/44 cases. Responses to CD20 or CD40 activation were independent of co-stimulation with IL-3, IL-4 or IL-7, and various cocktails of the different growth stimuli did not act synergistically
Hoping for a normal life:Decision-making on hematopoietic stem cell transplantation by patients with a hemoglobinopathy and their caregivers
Background: To provide insight into the perspectives of children and young adults with transfusion-dependent thalassemia and sickle cell disease and their caregivers regarding the decision for hematopoietic stem cell transplantation (HSCT). Procedure: A qualitative longitudinal multicenter study. Data collection consisted of 40 audio-recorded conversations between physicians and families and 77 interviews with patients and/or caregivers related to 27 unique cases, collected at different time points throughout the decision-making process. Results: Conversations and interviews revealed âhoping for a normal lifeâ as an overarching theme, consisting of four main topics: (i) âBuilding a frame of referenceâ refers to a process where patients or families try to obtain comprehensive information on HSCT and translate this to their situation to decide. (ii) âBalancing between loss and benefitâ reports the process of considering the advantages and disadvantages of continuing with supportive care to treat their disease versus choosing HSCT. (iii) âExperiencing the impact of HSCTâ describes the impactfull experience of the HSCT period by those who chose HSCT. (iv) âBalancing againâ refers to reflecting on the decision made. Conclusions: The hope for a normal life guided the decision-making process, described as a constant balance between the impact of the disease and HSCT. A structured approach to explore patientsâ and caregiversâ perspectives on HSCT decision-making is needed, where specifically discussing the impact of the disease and hope for a normal life need to be integrated in the process.</p
Hoping for a normal life:Decision-making on hematopoietic stem cell transplantation by patients with a hemoglobinopathy and their caregivers
Background: To provide insight into the perspectives of children and young adults with transfusion-dependent thalassemia and sickle cell disease and their caregivers regarding the decision for hematopoietic stem cell transplantation (HSCT). Procedure: A qualitative longitudinal multicenter study. Data collection consisted of 40 audio-recorded conversations between physicians and families and 77 interviews with patients and/or caregivers related to 27 unique cases, collected at different time points throughout the decision-making process. Results: Conversations and interviews revealed âhoping for a normal lifeâ as an overarching theme, consisting of four main topics: (i) âBuilding a frame of referenceâ refers to a process where patients or families try to obtain comprehensive information on HSCT and translate this to their situation to decide. (ii) âBalancing between loss and benefitâ reports the process of considering the advantages and disadvantages of continuing with supportive care to treat their disease versus choosing HSCT. (iii) âExperiencing the impact of HSCTâ describes the impactfull experience of the HSCT period by those who chose HSCT. (iv) âBalancing againâ refers to reflecting on the decision made. Conclusions: The hope for a normal life guided the decision-making process, described as a constant balance between the impact of the disease and HSCT. A structured approach to explore patientsâ and caregiversâ perspectives on HSCT decision-making is needed, where specifically discussing the impact of the disease and hope for a normal life need to be integrated in the process.</p
High Treosulfan Exposure is Associated with Early Toxicity in Pediatric Hematopoietic Stem Cell Transplantation: A Prospective Multicenter Study
n/
ADAMTS-13 and bleeding phenotype in von Willebrand disease
Background: The bleeding phenotype of von Willebrand disease (VWD) varies highly between patients and can only partly be explained by von Willebrand factor (VWF) parameters. By cleaving large VWF multimers into smaller, less active multimers, ADAMTS-13 is an important regulator of VWF activity. However, it is unknown what the role of ADAMTS-13 is in individuals with VWD. Objectives: We therefore studied how ADAMTS-13 activity is associated with the laboratory and bleeding phenotype in individuals with VWD. Methods: We measured ADAMTS-13 activity using the fluorescence resonance energy transfer substrate VWF 73 assay in 638 individuals with VWD in the nationwide cross-sectional Willebrand in the Netherlands study and in 36 healthy controls. The bleeding phenotype was assessed using the Tosetto bleeding score. Results: ADAMTS-13 activity was similar in individuals with VWD (109% ± 20.6%) and controls (110% ± 19.7%). ADAMTS-13 activity was higher in individuals with VWD with type 3 than those with type 1 (mean difference, 11.8%; 95% confidence interval [CI], 2.9%-20.8%) or type 2 (mean difference, 16.1%; 95% CI, 7.1%-25.1%). ADAMTS-13 activity was not associated with the Tosetto bleeding score (0.1 Tosetto bleeding score increase per 10% ADAMTS-13 increase, 95% CI, â0.2 to 0.3). Furthermore, ADAMTS-13 activity did not differ between individuals with and without a bleeding event during the year preceding blood sampling (mean difference, 1.4%; 95% CI, â2.1% to 4.9%). Conclusion: ADAMTS-13 activity was highest in individuals with type 3 VWD, but it had only minor associations with VWF parameters. ADAMTS-13 activity does not influence the bleeding phenotype in individuals with VWD
Stem cell transplantation for congenital dyserythropoietic anemia : an analysis from the European Society for Blood and Marrow Transplantation
Non peer reviewe
Delayed hemolytic transfusion reaction with hyperhemolysis after first red blood cell transfusion in child with ÎČ-thalassemia: Challenges in treatment
Background: Delayed hemolytic transfusion reaction (DHTR) can manifest with hyperhemolysis, a serious complication of red blood cell (RBC) transfusions. This has mostly been described in sickle cell anemia but occasionally in ÎČ-thalassemia. Treatment is challenging; immunosuppressive medication has been reported to be useful by some but not others. CASE REPORT: A 1.5-year-old girl with homozygous ÎČ-thalassemia was put on a regular RBC transfusion program because of anemia with stunted growth and abnormal bone development. After the first transfusion she developed DHTR with hyperhemolysis. Further RBC transfusions could not be avoided. Despite treatment with prednisone, immunoglobulins, rituximab, and azathioprine hemolysis continued. She received an allogeneic bone marrow transplantation after conditioning using cyclophosphamide, treosulfan, melfalan, and ATG. The transplantation was followed by treatment with cyclosporin A, methotrexate, and prednisone. Because of poor engraftment and later rejection, she received a retransplantation after conditioning using fludarabine instead of cyclophosphamide and was subsequently treated with prednisone, but hemolysis continued. Only after splenectomy did she no longer need RBC transfusions and the direct antiglobulin test turned negative. Discussion and Conclusion: Treatment of DHTR remains challenging. The role of immunosuppressive medication such as azathioprine, cyclosporin A, and rituximab remains to be seen. Splenectomy may be helpful. Mainstay is to minimize RBC transfusions as much as possible
Parental experiences in end-of-life decision-making in allogeneic pediatric stem cell transplantation: "Have I been a good parent?"
BACKGROUND: In pediatric hematopoietic stem cell transplantation (HSCT), the end-of-life (EOL) phase and the loss of the child is often characterized by a sudden deterioration of the child following a period of intensive curative treatment. This demands a fast transition for parents. Therefore, an understanding of the parents' perspective on decision-making in such a complex situation is needed. This study aims to gain insight in parental experiences in EOL decision-making in allogeneic pediatric HSCT. METHODS: A qualitative descriptive study was performed among parents of eight families. Data were thematically analyzed. RESULTS: All parents were aware of their child's deterioration. Six families were confronted with a rapid deterioration, while two families experienced a gradual realization that their child would not survive. Parental EOL decision-making in pediatric HSCT shows a reflective perspective on the meaning of parenthood in EOL decision-making. Two central themes were identified: "survival-oriented decision-making" and "struggling with doubts in hindsight." Six subthemes within the first theme described the parents' goal of doing everything to achieve survival. DISCUSSION: Parents experienced EOL decision-making mainly as a process guided by health care professionals (HCPs) based on the child's condition and treatment possibilities. The decision-making is characterized by following opportunities and focusing on hope for cure. In hindsight parents experienced doubts about treatment steps and their child's suffering. HCPs can strengthen the parental role by an early integration of palliative care, providing timely support to parents in the process of imminent loss. Advance care planning can be used to support communication processes, defining preferences for future care
- âŠ